Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Acromegaly
Interventions: IONIS-GHR-LRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more

Conditions: Prostate Cancer
Interventions: Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy; Biological · Procedure
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 30 Years to 70 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Dry Eye Disease
Interventions: GRF312 5%, Placebo Comparator; Drug · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Glendale, California • Grove, California • Newport Beach, California + 7 more

Conditions: Oral Mucositis
Interventions: SGX942, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Stress Disorders, Post-Traumatic
Interventions: Veterans Group Exercise (VGX), Illness Management and Recovery; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Coronavirus Infection
Interventions: NasoVAX, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, dose level 1, dose level 2, dose level 3, dose level 4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Daytona Beach, Florida • Ormond Beach, Florida • Duncansville, Pennsylvania

Conditions: Healthy
Interventions: AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypoxia, Hemodilution
Interventions: Noninvasive Physiological Monitoring Device; Device
Lead sponsor: Nihon Kohden; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 197
States / cities: Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more

Conditions: Autism Spectrum Disorder
Interventions: JNJ-42165279, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 35 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 9
States / cities: Dothan, Alabama • Phoenix, Arizona • Orange, California + 6 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more

Conditions: Hyperphosphatemia
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more

Conditions: Vitamin D Deficiency
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 6 Months to 6 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Samidorphan, Placebo, Oxycodone; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Thyroid Eye Disease
Interventions: Batoclimab, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more

Conditions: Restless Legs Syndrome
Interventions: Pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 52
States / cities: Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: ORJ-001, Placebo; Drug · Other
Lead sponsor: Oorja Bio, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Doral, Florida • DuBois, Pennsylvania

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: TQJ230, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 287
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more

Conditions: Acne Vulgaris
Interventions: B244, Placebo; Drug
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Diabetic Kidney Disease
Interventions: BMS-813160, Placebo matching with BMS-813160; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine 1.25 mg, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more

Conditions: Pain, Hernia
Interventions: Ibuprofen, Opioid Medication, Placebo, Ibuprofen + Opioid medication; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Search by objective public record fields.

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

Improving Mind/Body Health and Functioning With Integrative Exercise

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Hypoxia and Hemodilution Testing in Healthy Adult Volunteers

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Effects of Vitamin D Dose and Genotype of the Binding Protein in Infants and Children

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Study of ORJ-001 for the Treatment of IPF

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy